Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, the first modular mRNA workshop in China, has been delivered
Media
Sep 7, 2021
Walvax
On September 1, 2021, Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, was officially delivered. It is an advanced process combining modular buildings with conventionally built facilities, which allows for tighter construction and can accelerate the industrialization schedule of SARS-CoV-2 mRNA Vaccine. Construction of modular buildings can occur simultaneously with the site and foundation work, allowing projects to be completed in a shorter period.
Related Links
Feb 7, 2022
Walvax and Abogen Announce Safety and Immunogenicity Data from Phase 1 Clinical Study of AWcorna (SARS-CoV-2 mRNA Vaccine) Published in The Lancet Microbe
Learn More
May 13, 2022
Walvax announces the receipt of the purchase order from Morocco for the 13-valent pneumococcal polysaccharide conjugate vaccine
Learn More
Jul 5, 2023
Walvax publishes safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® in Human Vaccines & Immunotherapeutics
Learn More